Skip to content
Menu
Get the app WatchlistsPortfoliosAlerts
Pricing Sign in

PDS Biotechnology Corporation PDSB

Full chart Compare
Set alert

Price alert · PDSB

All alert types
0.87 USD -0.11 (-10.96%)

At closeNov 13, 2026, 7:44 PM EST

0.86 -0.01 -1.65%

After hours · Nov 13, 7:44 PM ET

0.75 Day range 0.99
0.201 52-week range 1.60
YTD
+13.32%
1 year
+3.27%

Discussion (81)

Sign in to join the discussion

frank fager PDSB 1 month ago #31

China tickers are hot because they're a scam. Total rig game special Hong Kong.

frank fager PDSB 2 months ago #32

PDSB

I am looking at this. It's a spec but it's looking good

They have complete 4 phase 2 studies and have 4 more going 8 in total, for multiple cancers. It involves T cells so it is a great match for Anktiva and the IA robotic lab T cells NK cells. 

Will do more on it tomorrow. Dr PSS has seen all of the trial results and he must like what he sees so he invested. 

Going from here to a FDA approval could easily be years. But ImmunityBio is marketing to the world and if these immunotherapies pan out they could market to the world too. 

It could easily be bought out by ImmunityBio or someone else in the future. 

PDSB

I may buy like 25,000 shares it's .45 a share 
Dr PSS investing and he is now on their board are huge positives.

Target high PDSB 8 months ago #33

$PDSB Top Institutional & Mutual Fund Holders
Based on the most recent 13F filings (reported through mid-February 2026):

  1. Armistice Capital LLC: ~5.18% (approx. 2.8 million shares)
  2. The Vanguard Group, Inc.: ~3.57% (approx. 1.95 million shares) 
  3. BlackRock, Inc.: ~0.95% (approx. 522k shares) 
  4. Geode Capital Management, LLC: ~0.95% (approx. 520k shares) 
  5. UBS Group AG: ~0.46% (approx. 251k shares)
Target high PDSB 10 months ago #35

$PDSB

In simple terms, PDS Biotech just announced a major update that could get their experimental cancer drug to patients much faster than originally planned.
Here is the breakdown of the news:

  1. What is the drug for?
    The drug (called PDS0101) is designed to treat a specific type of head and neck cancer caused by HPV16. This is a serious condition that the company predicts will become the most common head and neck cancer in the U.S. within the next decade.
  2. What happened with the FDA?
    The company met with the FDA (the government agency that approves drugs) and reached an "alignment" (an agreement) on how to test the drug.
  • The Shortcut: Originally, the company had to prove the drug helped patients live longer overall ("Overall Survival"). This takes a very long time to measure.
  • The New Plan: The FDA agreed that the company can now use a different measurement called "Progression-Free Survival" (how long a patient lives without their cancer getting worse).
  1. Why does this matter?
  • Speed: Because it is faster to see if a tumor stops growing than it is to see how long someone lives in total, the company can finish its study sooner.
  • Accelerated Approval: If the data looks good, PDS Biotech can apply for "Accelerated Approval." This is like getting a "provisional license" to sell the drug to patients while they finish the longer, final study.
  1. What’s next?
    The company has paused enrollment in their current large study briefly to officially update the rules (the "protocol") to match this new faster plan. They expect to resume shortly with this "fast track" approach.
    Summary for Investors/Patients:
    This is good news. It reduces the amount of time and money the company needs to spend on clinical trials and offers a clearer, faster path to getting the drug on the market and into the hands of patients who need it.
Target high PDSB 1 year ago #36

$PDSB
PDS Biotechnology Announces $5.3M Registered Direct Offering Of 5.8M Shares With Warrants At A Combined Price Of $0.91